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Abstract
Background: The Darlington and Northallerton Asthma Study is an observational cohort study
started in 1983. At that time little was published about long term outcome in asthma and the
contribution of change in reversible disease or airway remodelling to any excess deterioration in
function. The study design included regular review of overall and fixed function lung. We report
the trends over fifteen years.
Methods:  All asthmatics attending secondary care in 1983, 1988 and 1993 were recruited.
Pulmonary function was recorded at attendance and potential best function estimated according to
protocol. Rate of decline was calculated over each 5-year period and by linear regression analysis
in those seen every time. The influence of potential explanatory variables on this decline was
explored.
Results: 1724 satisfactory 5-year measurements were obtained in 912 subjects and in 200 subjects
on all occasions. Overall rate of decline (ml/year (95%CI)) calculated from 5-year periods was FEV1
41.0 (34.7–47.3), 28.9 (23.2–34.6) and best FVC 63.1 (55.1–71.2)ml/year, 45.8 (40.0–
51.6).The principal association was with age. A dominant cubic factor suggested fluctuations in the
rate of change in middle life with less rapid decline in youth and more rapid decline in the elderly.
Rapid decline was possibly associated with short duration. Treatment step did not predict rate of
deterioration.
Conclusions:  Function declined non-linearly and more rapidly than predicted from normal
subjects. It reports for the first time a cubic relationship between age and pulmonary function. This
should be taken into account when interpreting other articles reporting change in function over
time.
Background
It is recognised that the average decline in pulmonary
function is greater in asthmatic subjects than in the gen-
eral population [1,2]. This might be due to deterioration
in potentially reversible disease [3] or the development of
persistent obstruction following airway remodelling [4].
The published longitudinal studies do not differentiate
between the two possible mechanisms. The Darlington
and Northallerton Long Term Asthma Study was started in
1983 when little was known about long term outlook in
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asthmatics. Its objective was to observe mortality and
decline in pulmonary function in asthmatics sufficiently
severe to be referred for a hospital opinion. Decline in
best achievable function is proposed as a measure of the
airway remodelling. We accept that this decline might also
be associated with Chronic Obstructive Pulmonary Dis-
ease (COPD). This label implies a physiological diagno-
sis, but the condition, like asthma, is better defined in
terms of the underlying inflammation [5]. The diagnoses
are therefore not necessarily mutually exclusive. Changes
in best function are reported without prejudice to the
underlying type of inflammation whether asthmatic,
COPD, or both.
We wished this to be a population study as far as possible,
so we invited all subjects satisfying a broad definition of
asthma referred to a single-handed respiratory physician
in a well defined geographical area to participate. Very few
refused, but patients managed entirely in general practice
were necessarily excluded. Best function, assessed accord-
ing to a defined protocol [6] implicitly accepted in pub-
lished guidelines [7], and potential explanatory variables
were recorded prospectively at each visit. Smokers were
not specifically excluded, but smoking habit was taken
into account when the diagnosis was in doubt. Subjects
with severe established fixed obstruction were excluded.
Thus there was bias against the inclusion of asthmatic
smokers destined to develop fixed obstruction rapidly, so
we do not present any analyses confined to smokers.
Although it was not until the mid 1980's that the use of
prophylactic inhaled corticosteroids became standard
practice, the majority of our subjects were maintained on
inhaled steroids throughout the period, but the dose
intensified [8]. Therefore only the change in dose could
not account for any secular trends in decline in function.
In this paper we explore the influence of demographic and
other factors on change in function as observed over five
year intervals.
Methods
These, described in detail elsewhere [8-11] are summa-
rised and where directly relevant expanded below.
Subjects
All asthmatics currently attending secondary care clinics
in the Darlington and Northallerton Health Districts were
eligible for recruitment in 1983, 1988 and 1993, and
reviewed in 1988, 1993 and 1998. Asthma was diagnosed
clinically and confirmed by reversibility of FEV1 or peak
flow of at least 15% on more than one occasion, either
spontaneously, or in response to bronchodilator at any
time since referral [9]. Subjects were only eligible for the
study if they had been observed for at least one year before
entry, and if not stable when first reviewed, entry was
deferred by three months in an attempt to achieve stabil-
ity. Socio-demographic variables were recorded as previ-
ously reported [10]. The first group of this dynamic cohort
study was recruited during the calendar year 1983 but sub-
sequent review and recruitment was between the 1st April
and the 31st March in subsequent 12-month periods[11].
Allowance for the extra 3 months of the first interval has
been made in calculating rate of change. Subjects are
included in this report provided they had two technically
satisfactory measurements of actual FEV1 or two estimates
of best FEV1 or best FVC according to protocol.
Social and demographic variables
The following variables recorded included: age, gender,
height, duration of asthma, atopy, childhood asthma,
smoking habit and lifetime amount smoked, social class.
Duration of asthma was determined from the first onset
or from relapse after a symptom free interval of at least
five years, if this was applicable. Atopy was determined by
at least one of the following skin tests resulting in a diam-
eter at least 3 mm greater than control: D Pterynissimus,
cat, grass pollen, A fumigatus. Childhood asthma was
defined as a childhood history of recurrent lower respira-
tory tract symptoms with wheeze, in the absence of a
localised structural damage such as bronchiectasis. It was
sub-divided into those with (Gap Asthmatics) and with-
out (Continuous since Childhood) a symptom free gap of
at least five years. Never smokers were those smoking less
than one cigarette a day for one year. Ex-smokers had been
abstinent for at least three months at the time of examina-
tion. The lifetime amount smoked was determined from
the average consumption (expressed in packs of 20 ciga-
rettes) multiplied by the duration of smoking to give a fig-
ure in pack-years.
Therapeutic regimen
This was characterised by the use of long acting beta ago-
nists and the corticosteroid step: none, low dose inhaled
(<800 micrograms per day), intermediate dose inhaled
(800–1000 micrograms per day), high dose inhaled
(>1000 micrograms per day), oral 1–9 mgs per day, oral ≥
10 mgs per day, unstable (treatment not mutually agreed
as satisfactory over the last three months).
Pulmonary function
Actual function
Actual function was that recorded at attendance.
Best function
This was estimated according to the published protocol
[6]. The notes were searched from January 1st of the previ-
ous year, and the highest value, including the after-bron-
chodilator reading at attendance, was accepted as best
subject to the following.
(a) If >80% predicted (Cotes [12]); after-bronchodilatorBMC Pulmonary Medicine 2005, 5:2 http://www.biomedcentral.com/1471-2466/5/2
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(b) If 70–80% predicted; after-bronchodilator and stable
on mutually agreed satisfactory preventative treatment
with twice daily recording of peak flow for one week
(c) If <70% of predicted; after-bronchodilator with formal
trial of corticosteroids (prednisolone 30 mgs for at least
five days with stability of peak flow for at least 48 hours)
If the above was not already satisfied, best function was
immediately established according to the protocol.
Measurement
Spirometry was performed using a rolling wedge spirom-
eter (Vitalograph Limited) and peak flow with the mini
peak flow meter (Clement Clark Limited). Actual function
was measured opportunistically at the clinic in current
attenders and at a special clinic for those who had been
discharged. One of three research fellows, one of two
research nurses or CKC were responsible for checking cur-
rent pulmonary tests in the clinical records and perform-
ing further tests when required by protocol for best
function.
Ethical approval
This was obtained from the Darlington, Northallerton
and South Durham Ethics Committees at various stages of
the study.
Statistical analysis
The principal independent variable was change during
each 5-year period so each individual contributed up to 3
observations to the analysis. For the 200 subjects with
observations on all four occasions a secondary analysis
could be based on decline over 15 years, and for each of
these subjects the mean rate of decline was estimated from
the four observations using linear regression analysis.
Best and actual/best peak flow measured independently
of the spirometric outcome variables were chosen as the
functional potential predictors of outcome. This approach
was taken to avoid the mathematical relationship
between baseline level and change that applies if the
spirometric variables are used as predictors of outcome.
Many of these potential predictive variables are correlated
with each other and there are arguments for and against
models examining the effect of socio-economic variables
with or without allowance for the respiratory function of
the patients and their age. We present a relevant selection
from the large range of unrestricted and hierarchical mod-
els that we constructed.
We allowed for the inevitable regression to the mean asso-
ciated with outcome measures subject to appreciable var-
iability. Initially the starting value of an outcome
functional variable was regressed against a full set of
potential predictors of this function in order to generate a
set of residuals indicating the extent to which an individ-
ual starting measurement is higher or lower than would
be expected. Then the change in function was regressed
against the residual. The new set of residuals indicates the
extent to which the apparent rate of change is affected by
regression to the mean enabling an adjusted rate of
change to be calculated. This adjusted change in function
was then taken as the dependent variable in subsequent
analyses. These included the univariate effect of potential
risk factors on the adjusted change in function. In the
multivariate analyses we omitted variables which were
consistently non-significant, but all others are retained in
the presentation. Models are shown with and without the
inclusion of age. Univariate analysis showed that there
were cubic relationships between change in function and
age and duration. The cubic terms are retained in the mul-
tivariate presentation. We also examined interactions
between predictor variables where there was some a priori
reason for believing that such an interaction was plausible
but none was demonstrated.
Results
General
Of 1138 subjects recruited, 155 died before the first
review, 49 were lost to follow up and 22 did not have sat-
isfactory spirometric tests. The remaining 912 had at least
one paired result of actual or best FEV1 or best FVC and
200 had satisfactory assessments of best FVC on all four
occasions. Demographic details at entry are given in Table
1. There were no relevant differences in social factors
between the subjects observed on all four occasions and
the rest. Current smokers represented approximately 13%
of the population in 1983/88 and 10% in 1993/98 with a
mean tobacco load of 29.2 (ex-smokers 27.6) and
21.4 (ex-smokers 13.2) pack years. Ever-smokers were
significantly older than never-smokers (53.9 v 44.9 years
p < 0.001), but allowing for age, the atopic status of ever-
smokers and never-smokers was the same. The proportion
of subjects stable on inhaled or oral steroids rose from
66.5% in 1983 to 82.1% in 1988 with no increase there-
after. Higher doses (> = 800 micrograms) of inhaled ster-
oids increased from 30.8% in 1988 to 41.6% in 1998.
Change in function
The mean annual decline in function calculated using all
five-year intervals (Table 2) was greater than expected
when compared with predicted values and when
expressed as %predicted [12] there were no consistent dif-
ferences in the rates of decline of male and female never-
smokers. As the confidence intervals suggest, standard
deviations were large indicating a wide distribution of
changes in different individuals. There was no secular
trend in outcome in successive calendar periods. Figure 1
shows changes over 5, 10 and 15 year periods after entryBMC Pulmonary Medicine 2005, 5:2 http://www.biomedcentral.com/1471-2466/5/2
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against predicted [12] (improved >7.5%, no change, dete-
riorated >7.5%). Actual FEV1 improved in approximately
one quarter and best FVC in rather less than 20% of sub-
jects. The proportion of subjects showing deterioration in
FEV1 >7.5% (35%) did not increase with time after entry,
but excess decline in FVC was observed in more subjects
after 15 year's observation (58%) than after five (37%) (χ2
for trend, 59.0 (p < 0.001)).
For the 200 subjects with complete observations over 15
years the mean rate of decline was similar to that observed
over five year periods, but the standard deviation of the
rates of decline was half that of the 5-year estimates,
reflecting greater accuracy from multiple measurements.
Even when calculating change this way several individuals
improved or showed excessive loss in function against
predicted [12].
Associations with entry variables
As there was no secular trend in the change of function
over the five year periods, the date of observation is not
considered in the analyses below.
All subjects: 5-year intervals
Univariate analysis
The univariate relationships between the potential
explanatory variables and change in function after allow-
ance for regression to the mean are summarised in Table
3. These are derived from all available pairs of observa-
tions at five year intervals. The strong associations with
age are not linear. This is demonstrated in fig 2 which
shows the fitted plots of the cubic equations for the unad-
justed rate of decline for all three measures. The maxi-
mum decline was in the mid 40's for all three variables
(actual FEV1 44 ml/yr; best FEV1 56 ml /yr; best FVC 70
Table 1: Details of subjects at entry
Male Female
n 457 455
Age (years)(sd) 50.4(15.4) 49.3(16.3)
Duration of asthma (years)(sd) 17.0(16.2) 18.6(15.4)
Atopic n(%) 258(56.5) 227(49.9)
Asthma n(%) childhood 124(27.1) 131(28.8)
gap 53(11.6) 42(9.2)
adult 280(61.3) 282(63.3)
Social Class n(%) 1–2 131(28.8) 139(30.5)
3 168(36.9) 180(39.6)
4–5 156(34.3) 136(29.9)
Smoking Habit n(%) never 147(32.2) 247(54.3)
ever 239(52.3) 161(35.4)
current 71(15.5) 47(10.3)
Pulmonary Function(sd) Actual FEV1 l. 2.50(1.09) 1.97(0.79)
Best FEV1 l. 2.60(1.08) 2.08(0.82)
Best FVC l. 4.17(1.25) 3.05(0.84)
Best PEF l/min 465.7(113.7) 382.0(85.1)
Actual/Best PEF % 84.4(13.7) 83.2(15.9)
Table 2: Annual Decline in Pulmonary Function calculated from the mean of all 5-year paired observations, and by linear regression 
over 15 years in the 200 subjects with all four observations
Annual Decline n Actual FEV1 l. Best FEV1 l. Best FVC l.
Males Over 5 Years All Subjects 776 41.0 (34.7–47.3) 42.9 (37.5–48.3) 63.1 (55.7–71.2)
Never smokers 256 34.2 (22.2–46.2) 33.4 (22.7–44.1) 49.2 (35.6–62.8)
Over 15 Years 85 46.7 (38.7–54.7) - 64.7 (54.6–74.8)
Females Over 5 Years All Subjects 848 28.9 (23.2–34.6) 34.4 (29.8–39.0) 45.8 (40.0–51.6)
Never smokers 375 28.7 (22.4–38.8) 30.6 (22.2–35.2) 45.2 (36.4–54.0)
Over 15 Years 115 24.7 (14.8–31.2) - 44.6 (37.9–51.3)BMC Pulmonary Medicine 2005, 5:2 http://www.biomedcentral.com/1471-2466/5/2
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The proportion of all subjects and never-smokers showing decline (>7.5%), no change, or improvement (>7.5%) in function  against predicted over 5, 10 and 15 years Figure 1
The proportion of all subjects and never-smokers showing decline (>7.5%), no change, or improvement (>7.5%) in function 
against predicted over 5, 10 and 15 years.BMC Pulmonary Medicine 2005, 5:2 http://www.biomedcentral.com/1471-2466/5/2
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ml/yr). During the eighth decade rate of decline in
function recovered towards the published predicted val-
ues [12] to 27, 29 and 49 ml/yr respectively.
There were no statistically significant relationships with
atopy. Longer duration of asthma was significantly associ-
ated with favourable outcome for all variables. In all cases
a cubic relationship between loss of function and dura-
tion suggests high initial rates of loss (actual FEV1 55 ml/
yr; best FEV1 51 ml/yr; best FVC 74 ml/yr at one year),
with improvement to a plateau at around 20 years dura-
tion (30 ml/yr, 37 ml/yr and 45 ml/yr). Childhood
asthma was significantly associated with a relatively
favourable outcome, though this benefit was only seen in
those for whom asthma had been continuous. The out-
come of the 'gap asthmatics' was similar to those with
adult onset. Higher social class was associated with worse
outcome, significantly so for best FEV1. Low initial
function and worse control as assessed by actual/best PEF
both predicted less loss in actual FEV1. Although there
were no significant associations with current smoking sta-
tus, there was significantly greater loss in best FVC with
amount smoked.
Multivariate analysis
As childhood asthma, duration of asthma and age at entry
are potentially confounded and were significant in some
of the univariate analyses, we performed a series of multi-
variate analyses progressively including each in turn.
Tables 4, 5, 6 show the results after the inclusion of dura-
tion and then age. Male gender was significantly associ-
ated with greater decline in best FEV1 and, in contrast to
the univariate analysis, best FVC. After the inclusion of
duration, childhood asthma was still associated with
favourable outcome in both actual FEV1 and best FVC,
but it was displaced by age in all the models. Duration
remained significantly associated with less change in best
FVC even after allowance for age. In both models, actual
FEV1 declined less with lower entry actual/best PEF. Best
Table 3: Rate of loss of Function Univariate Coefficients (ml per year) (after allowance for regression to the mean)
Actual FEV1 Best FEV1 Best FVC
Estimate 95% CI Estimate 95% CI Estimate 95% CI
Gender (male v female) 7.7 0.8+,16.1 6.2 2.5+,14.9 12.2 2.5,21.9
Age at entry (per decade) (difference from age 50) Linear 5.6+ 11.4+,0.2 10.1+ 15.9+,4.8+ 2.1+ 8.7+,4.5
quadratic 4.3+ 6.0+,2.5+ 5.0+ 6.8+,3.3+ 4.5+ 6.5+,2.6+
cubic 1.3 0.3,2.3 2.0 1.0,2.9 1.4 0.3,2.6
Duration of asthma at entry (per decade) 
(difference from duration 20 yrs)
Linear 3.1+ 7.4+,1.1 0.5 3.8+,4.8 0.1 4.8+,5.0
quadratic 3.6 0.6,6.6 2.7 0.5+,5.8 5.6 2.2,9.0
cubic 0.9+ 1.6+,0.1+ 0.9+ 1.7+,0.1+ 1.4+ 2.3+,0.6+
Atopic 5.7+ 14.2+,2.8 0.2 8.5+,8.9 3.0+ 12.7+,6.7
Childhood asthma (versus no childhood asthma) Gap 3.4+ 16.7+,9.9 1.4 12.2+,15.0 4.0+ 19.4+,11.3
Yes 20.8+ 30.6+,10.9+ 10.6+ 20.9+,0.4+ 22.0+ 33.3+,10.6+
Social Class (versus classes 1 and 2) Three 6.3+ 16.5+,3.8 11.2+ 21.7+,0.8+ 9.2+ 20.8+,2.3
Four and Five 10.2+ 21.0+,0.7 14.5+ 25.6+,8.3+ 8.6+ 21.0+,3.9
Amount smoked (per 10 pack years) 1.5 0.6+,3.7 0.2 2.1+,2.4 2.9 0.4,5.4
Best PEF(per 10% deficit) 3.3+ 5.3+,1.2+ 2.8+ 4.8+,0.7+ 0.4+ 2.7+,2.0
Actual/Best PEF(10% deficit) 12.7+ 15.6+,9.8+ 2.8+ 6.2+,0.6 0.6+ 4.1+,2.8
(+) Indicates relative gain in function
The relationship between age and annual change in function,  observed over 5-year periods Figure 2
The relationship between age and annual change in function, 
observed over 5-year periodsBMC Pulmonary Medicine 2005, 5:2 http://www.biomedcentral.com/1471-2466/5/2
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FEV1 declined more rapidly in those with a high initial
best PEF. When age was not included in the model,
membership of social classes 1 and 2 remained associated
with unfavourable outcome for best FEV1.
Height (not tabulated) was consistently directly associ-
ated with decline at a significance level of the order of
15% in univariate and multivariate analyses. In the latter
analyses, height suppressed the associations with gender
and social class. There were no significant associations
with instability of regimen, nor with steroid step or the
regular prescription of bronchodilators. None of the mod-
els considered made any relevant difference to the shape
or gradients of the curves shown in fig 2.
200 Subjects: decline estimated using all four observations
Generally similar univariate associations were demon-
strated. However on multivariate analysis, amount
smoked remained in the FVC model (coefficient 13.3 ml/
year per 10 pack years P = 0.020), and the effect of gender
Table 4: Multivariate Coefficients (sd) for Rate of loss of Actual FEV1 (after allowance for regression to the mean)
Age Excluded Age Included
Coefficient p Coefficient p
Gender (male v female) 5.5 (4.8) 0.25 5.7 (4.7) 0.23
Asthma since childhood 13.5+ (5.1) 0.008 4.9+ (5.8) 0.40
Social Classes 1 & 2 (v. classes 4 & 5) 4.8 (5.4) 0.65 1.8 (5.4) 0.88
Social Class 3 (v. classes 4 & 5) 1.1 (5.1) 0.6+ (5.0)
Amount smoked (per 10 pack years) 1.8 (1.2) 0.13 1.0 (1.2) 0.39
Best PEF(per 10% deficit) 1.2+ (1.2) 0.33 0.9+ (1.2) 0.41
Actual/Best PEF(10% deficit) 12.0+ (1.6) <0.0001 13.2+ (1.6) <0.0001
Age at entry (per decade)
(difference from age 50)
Linear 3.5+ (3.1)
quadratic 4.9+ (0.9)
cubic 1.2 (0.6) 0.02
Duration of asthma at entry (per decade) 
(difference from duration 20 yrs)
Linear 1.3 (2.8) 2.0+ (2.4)
quadratic 3.2 (1.5) 0.9 (0.5)
cubic 0.85+ (0.38) 0.03 2.5+ (0.39) 0.52
(+) Indicates relative gain in function
Table 5: Multivariate Coefficients for loss of Best FEV1 (after allowance for regression to the mean)
Age Excluded Age Included
Coefficient (sd) p Coefficient (sd) p
Gender (male v female) 11.3 (5.1) 0.03 11.9 (5.4) 0.02
Asthma since childhood 5.1+ (5.3) 0.34 1.1+ (6.0) 0.86
Social Classes 1 & 2 (v. classes 4 & 5) 13. (5.7) 0.05 10.7 (5.6) 0.11
Social Class 3 (v. classes 4 & 5) 2.9 (5.3) 1.4 (5.2)
Amount smoked (per 10 pack years) 0.7 (1.3) 0.60 0.5 (1.3) 0.71
Best PEF(per 10% deficit) 3.4+ (1.3) 0.008 3.1+ (1,2) 0.01
Actual/Best PEF(10% deficit) 0.7+ (1.8) 0.71 1.4+ (1.8) 0.44
Age at entry (per decade)
(difference from age 50)
Linear 8.4+(3.2)
quadratic 5.1+ (0.9)
cubic 1.8 (0.5) 0.0003
Duration of asthma at entry (per decade) 
(difference from duration 20 yrs)
Linear 3.1 (2.4) 0.2 (2.4)
quadratic 2.5 (1.6) 0.4 (1.6)
cubic 0.91+ (0.39) 0.02 0.29+ (0.40) 0.46
(+) Indicates relative gain in functionBMC Pulmonary Medicine 2005, 5:2 http://www.biomedcentral.com/1471-2466/5/2
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was stronger in both models (actual FEV1 23.8, actual
FVC 19.8 ml/year, (P < 0.001). Height was again consist-
ently directly associated with decrease in function at a sig-
nificance level of the order of 15%. When height was
included to allow for its association with gender, the dif-
ference in rate of decline in FEV1 between males and
females was substantially reduced to 12.5 ml per year (p =
0.010) and was no longer significant for best FVC (p =
0.14).
Discussion
The hypothesis that persistent airway obstruction may
develop in asthmatics implies that persistent airway
obstruction and reversible obstruction associated with
asthma are not mutually exclusive diagnoses However if
COPD is regarded as a syndrome; this implies a non-asth-
matic inflammatory process [5]. As the two types of
inflammation need not be mutually exclusive, some asth-
matics might have both types raising the possibility of an
interaction between the two processes in some individu-
als, 'The Dutch Hypothesis' [13]. We have already shown
that on cross sectional analysis green sputum, which is a
feature of severity in COPD [14], is associated with dimin-
ished best function independent of smoking habit [15].
We are satisfied that our subjects satisfied the clinical cri-
teria for asthma and had the relevant inflammatory proc-
ess. Of course, the study is not of the entire asthmatic
population as some individuals will remain undiagnosed
while others will have been managed entirely in general
practice, but all those referred to hospital and willing were
entered into the study. We believe that the referral thresh-
old was relatively low, and very few patients were referred
outwith the local area. The subjects were recruited by a
single handed hospital physician, with no other selection.
There were no differences in the demography or function
of those entering at different times [11]. Most were stable
on maintenance corticosteroids [8].
The rate of decline of actual FEV1 was similar to that
reported by Ulrik [1] (38 ml/year) and Lange [2] (50 ml/
year). This study demonstrates for the first time that
decline in best after bronchodilator function, the defini-
tive physiological measurement for COPD [16], is similar
to that of actual function. Actual/best PEF tended to
improve over the period [8], so measurement of actual
FEV1 potentially under-estimates any decline in best
FEV1, but in practice loss of actual FEV1was not relevantly
different from that of best FEV1.
As in the previous studies [1,2] the rate of decline of actual
FEV1 is greater than that suggested by reference equations
[12,17] which are derived from cross-sectional data. Val-
ues derived from longitudinal data may differ from cross-
sectional observations for a number of reasons [18,19].
These include a cohort effect and, with lung function, loss
of height with ageing which will mask decline in the cross
sectional tables. We allowed for loss of height by using
height at the start of each 5-year period. After discounting
this there was little difference between the genders, the
principal association with change in function being the
age of the subjects. Longitudinal studies suggest increased
loss of FEV1 in elderly normal subjects [20-22], but the
rate of decline in our study is greater at all ages than that
reported from the general population [20]. Our results
suggest that that a cubic model involving age is
Table 6: Multivariate Coefficients for Rate of loss of best FVC (after allowance for regression to the mean)
Age Excluded Age Included
Coefficient (sd) p Coefficient (sd) p
Gender (male v female) 10.8 (5.6) 0.05 11.4 (5.6) 0.04
Asthma since childhood 16.0+ (6.0) 0.007 4.7+ (6.9) 0.49
Social Classes 1 & 2 (v. classes 4 & 5) 10.7 (6.4) 0.13 7.5 (6.4) 0.29
Social Class 3 (v. classes 4 & 5) 0.2+ (6.0) 1.4+ (5.9)
Amount smoked (per 10 pack years) 1.9 (1.4) 0.18 0.9 (1.4) 0.52
Best PEF(per 10% deficit) 0.6+ (1,.4) 0.65 0.6+ (1.9) 0.67
Actual/Best PEF(10% deficit) 1.3 (1.8) 0.47 0.1 (1.9) 0.94
Age at entry (per decade)
(difference from age 50)
Linear 2.1+ (3.7)
quadratic 4.0+ (1.0)
cubic 1.4 (0.6) 0.02
Duration of asthma at entry (per decade)
(difference from duration 20 yrs)
Linear 4.0 (2.8) 0.8 (2.8)
quadratic 5.2 (1.7) 3.2 (1.8)
cubic 1.46+ (0.44) 0.001 0.97+ (0.46) 0.03
(+) Indicates relative gain in functionBMC Pulmonary Medicine 2005, 5:2 http://www.biomedcentral.com/1471-2466/5/2
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appropriate for all of the three measures of respiratory
function that we have analysed. Although the pattern in a
particular individual cannot be determined from these
computed curves, they strongly suggest that decline is not
linear. The interpretation of the pattern of change is criti-
cally dependent on its normal course. The critical points
on the curve include the age at which maximum life-time
function is achieved and the possibility of a plateau,
before deterioration starts The age when personal best is
achieved is variously estimated between the early twenties
and the late thirties [19], and may well vary from person
to person. In looking for a plateau phase Robbins et al
[23] demonstrated both positive and negative slopes in
different individuals. Any decline seen where improve-
ment or no change is anticipated must be excessive and so
the slow decline that we observed in the third decade may
be an under-representation of the true loss of function. It
is more difficult to explain the faster decline in early com-
pared to late middle age. As the entry criteria of this study
were a diagnosis of asthma with no attempt to exclude co-
existent COPD, it is possible that this reflects a period of
life when the effects of the inflammatory process associ-
ated with COPD are particularly apparent. In subjects
where asthma and COPD co-exist, COPD might contrib-
ute to presentation in these subjects, and decline in func-
tion might be particularly rapid especially if there were
interaction between the two inflammatory processes. The
above is compatible with the apparently unsustainable
rates of decline observed early in COPD as in the Euro-
scop study [24]. We confirmed that decline accelerates
after in late life in these asthmatics as it does in normal
subjects [[20,21], and [22]].
Outcome in successive periods is necessarily confounded
by the effects of management and attrition. Attrition is
particularly relevant to the analysis of change in function,
as the most powerful predictor of survival in these subjects
is best function [11]. Higher dose of inhaled corticoster-
oids at the start of an observation period was not associ-
ated with better outcome within the same period. This is
unsurprising because a higher dose reflects more severe
disease. More surprisingly, there was also no evidence that
the higher average dose in successive periods was associ-
ated with a favourable secular trend in observed, or
maximum, function. Nevertheless in contrast, actual/best
peak flow improved [8] and standardised mortality
declined with time [11]. The latter was reduced twofold
although subjects on higher therapeutic steps remained
more likely to die even after allowance for other risk fac-
tors including best function. It may be that clinicians are
able to recognise subjects of poor prognosis irrespective of
function, but are more successful in reducing mortality
than loss of function by adjustment of therapy. None of
these considerations necessarily imply that the use of
inhaled corticosteroids is ineffective in terms of function.
As there were, of necessity, no controls, any effect of treat-
ment, dictated by clinical need, is impossible to confirm.
Improvement in functional outcome might have been
confounded by reduced mortality in those with severe dis-
ease, or the dose response curves for reduction of mortal-
ity might be very different from those for prevention of
airway remodelling.
We depended primarily on patient recall in making a diag-
nosis of childhood asthma. Although we had a low
threshold for accepting the diagnosis, presumably recall
would be more consistent when childhood symptoms
were severe. This might produce a bias in favour of dem-
onstrating associations. Nevertheless the univariate
associations with change in function were stronger in
those who claimed that they had had persistent symptoms
since childhood, than in those who recalled childhood
asthma after a gap of at least five years. The outcome in
gap asthmatics was similar to those with adult onset, but
surprisingly subjects with symptoms persistent since
childhood showed a more favourable trend. This appears
to be inconsistent with the long established observation
that childhood asthma compromises adolescent and early
adult lung function and that this is related to persistent
symptoms [25,26]. However duration is probably the crit-
ical factor. The history of asthma is likely to be long in
adults with symptoms persistent from childhood and
rapid decline is shown to be associated with short dura-
tion. Although these subjects did have relatively poor lung
function at entry to the study [10], probably reflecting
their function on reaching maturity, it does not necessar-
ily follow that retarded development will be succeeded by
an excessive rate of decline later in life. It may be that at
any age whether in childhood or adulthood the first dec-
ade of the disease is critical in determining loss of func-
tion. This might not be true in those with pure COPD, and
explain why our findings are contrary to the 'horseracing
effect' (the horse that runs fastest continues to extend its
lead) as described by Fletcher in his classical population
studies [27]. There the comparison was with normal sub-
jects rather than those with established airway disease
with differing lengths of history.
The effect of smoking appeared small, but there were few
current smokers and the tobacco load was light. The study
was not designed to observe the effects of tobacco
smoking in asthma; the separate analysis of non-smokers
was intended to describe the decline in the function of
asthmatics unencumbered by the effects of cigarette
smoking. It is inevitable that we have underestimated the
potential association between smoking and decline in
function in asthma and so do not suggest that the effect of
smoking in asthmatics in general is unimportant.BMC Pulmonary Medicine 2005, 5:2 http://www.biomedcentral.com/1471-2466/5/2
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The association between low initial actual/best function,
implying poor control, and apparently favourable out-
come is highly likely to reflect response to treatment.
There was a strong relationship between low social class
and poor control in the 1983 entry [10]. This may account
for some of the paradoxical benefit of lower social class,
possibly even hiding a real disadvantage.
Conclusions
We present the decline in function in a dynamic cohort of
adult asthmatics observed over fifteen years. The majority
were treated with inhaled corticosteroids throughout the
period. As there are no internal asthmatic or normal con-
trols our study cannot determine definitively whether
there is excess decline in the pulmonary function of adults
managed conventionally with inhaled cortico-steroids. It
does suggest, however, that the dose of inhaled steroids
may not be critical over the recommended range. Our
study confirms that the pattern of decline in actual and
best ventilatory function is similar. This is important
when comparing this study with epidemiological exer-
cises where actual rather than best function has been
measured. Furthermore these original findings in respect
of the cubic effect of age should be taken into account
when interpreting other articles reporting age effects on
function, particularly where analysis of cross-sectional
observations may imply that decline in the function is
linear.
Competing interests
The author(s) declare that they have no competing
interests.
Authors' contributions
CKC conceived the study and was responsible for design
of data forms, recruitment and all the clinical aspects. RJP
undertook the analysis of data. Both authors read and
approved the final manuscript.
Acknowledgements
We wish to thank former research fellows: NK Murthy, PM Roy, AA Gat-
nash, M Mamun and H Dasgupta for their clinical contributions, and Urike 
Paulus and Mirjam Göhler for help with the analysis.
This study was supported at various phases by Glaxo Welcome Plc (Dun-
can Flockhart Ltd and Allen and Hanbury's Ltd), the National Asthma Cam-
paign and Breath North (in association with the British Lung Foundation) 
and local research funds.
References
1. Ulrik CS, Backer V, Dirksen A: A 10 year follow up of 180 adults
with bronchial asthma: factors important for the decline in
lung function. Thorax 1992, 47:14-18.
2. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G: A 15-year follow-
up study of ventilatory function in adults with asthma. New
England Journal of Medicine 1998, 339:1194-200.
3. Woolcock A: Corticosteroid-resistant asthma: Definitions. Am
Rev Respir Dis 1996, 154(Suppl 2 pt2):S45-48.
4. Wilson JW, Bamford TL: Assessing the evidence for remodel-
ling of the airway in asthma. Pulmonary Pharmacology &
Therapeutics. 2001, 14:229-47.
5. Jeffrey PK: Morphology of the airway wall in asthma and in
chronic obstructive pulmonary disease. Am Rev Respir Dis 1991,
143:1152-1158.
6. Connolly CK, Prescott RJ, Alcock SM, Gatnash AA: Actual over
best function as an outcome measure for asthma. Respir Med
1994, 88:453-459.
7. British Thoracic Society, Scottish Intercollegiate Guidelines Network:
British Guideline on the Management of Asthma. Thorax 2003,
58(Suppl 1):.
8. Connolly CK, Alcock SM, Prescott RJ: Management and control
of asthma as assessed by actual/best function and corticos-
teroid usage between 1980 and 1993/4.  Eur Resp J 1998,
12:859-864.
9. Connolly CK, Chan NS, Prescott RJ: The relationship between
age and duration of asthma and the presence of persistent
obstruction in asthma. Post Grad Med 1988, 64:422-425.
10. Connolly CK, Chan NS, Prescott RJ: The influence of social fac-
tors on control of asthma. Post Grad Med J 1989, 65:282-285.
11. Connolly CK, Alcock SM, Prescott RJ: Mortality in Asthmatics
over 15 years; a dynamic cohort study from 1983 – 1998. Eur
Respir J 2002, 19:593-598.
12. Cotes JE, Lung Function: 4th edition. Oxford, Blackwell Scientific
Publications; 1979. 
13. Orie NG, Sluiter HJ, de Vries K, Tameling GJ, Witkop J: The host
factor in bronchitis. In Bronchitis: an international symposium, 27–29
April 1960 University of Gronigen. Assen: Royal van Gorcum;
1961:43-59. 
14. Stockley RA, O'Brien C, Pye A, Hill SL: Relationship of sputum
color to nature and outpatient management of acute exac-
erbations of COPD. Chest 2000, 117:1638-45.
15. Connolly CK, Murthy NK, Alcock SM, Prescott RJ: Sputum and
pulmonary function in asthma. Chest 1997, 112:994-9.
16. The COPD Guidelines Group of the Standards of Care Committee of
the BTS: BTS Guidelines for the management of chronic
obstructive pulmonary disease. Thorax 1997, 52(supp 5):.
17. Quanjer PhH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yer-
nault JC: Lung volumes and forced ventilatory flows. Eur Respir
J 1993, 6(suppl 16):5-40.
18. Vollmer WM, Johnson LR, McCamant LE, Buist AS: Longitudinal
versus cross-sectional estimation of lung function decline –
further insights. Statistics in Med 1988, 7:685-96.
19. Weiss ST, Ware JE, Schouten J, Rucken B, eds: American Thoracic
Society-European Respiratory Society Longitudinal Data
Workshop. Am Rev Respir Dis 1996, 154(6 part 2 Suppl):.
20. Ware JH, Dockery DW, Louis TA, Xu X, Ferris BG Jr, Speizer FE:
Longitudinal and cross-sectional estimates of pulmonary
function decline in never-smoking adults. Am J Epidemiol 1990,
132:685-700.
21. Nakadate T: Longitudinal observation of pulmonary function
decline in male Japanese workers: design, baseline results,
and methodological considerations of handling pulmonary
function data. Industrial Health 1998, 36:305-11.
22. Baltopoulos G, Fildisis G, Karatzas S, Georgiakodis F, Myrianthefs P:
Reference values and prediction equations for FVC and
FEV(1) in the Greek elderly. Lung 2000, 17:201-12.
23. Robbins DR, Enright PL, Sherrill DL: Lung function development
in young adults: is there a plateau phase? Eur Respir J 1995,
8:768-72.
24. Burge PS: EUROSCOP, ISOLDE and the Copenhagen city
lung study. Thorax 1999, 54:287-288.
25. Martin AJ, Landau LI, Phelan PD: Lung function in young adults
who had asthma in childhood.  Am Review of Respir Dis 1980,
122:609-16.
26. Rasmussen F, Taylor DR, Flannery EM, Cowan JO, Greene JM, Herbi-
son GP, Sears MR: Risk factors for airway remodelling in
asthma manifested by a low post bronchodilator FEV1/vital
capacity ratio: a longitudinal population study from child-
hood to adulthood.  Am J Respir & Critical Care Med 2002,
165:1480-1488.
27. Fletcher CM, Peto R, Tinker CM, Spizer FE: The Natural History
of Chronic Bronchitis and Emphysema. Oxford, Oxford Uni-
versity Press; 1976. Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Pulmonary Medicine 2005, 5:2 http://www.biomedcentral.com/1471-2466/5/2
Page 11 of 11
(page number not for citation purposes)
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2466/5/2/prepub